You are here

Veltassa

Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks

Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks

BioSpace

Gilead Sciences

Flag link:

Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study

Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study

Pharmaceutical Business Review

chronic kidney disease

clinical trials

Flag link:

Galenica to Buy Relypsa for $1.53 Billion

Galenica to Buy Relypsa for $1.53 Billion

TheStreet.com

Flag link:

A Great Month For Relypsa

A Great Month For Relypsa

Seeking Alpha

Flag link:

3 Big Battles Brewing in Biotech

3 Big Battles Brewing in Biotech

Motley Fool

Synergy Pharmaceuticals

Flag link:

Relypsa Rises on Bullish Veltassa Report; AstraZeneca, Sanofi Take Note

Relypsa Rises on Bullish Veltassa Report; AstraZeneca, Sanofi Take Note

Bidness, ETC

Flag link:

Relypsa's Veltassa Will Be Embraced By Physicians

Relypsa's Veltassa Will Be Embraced By Physicians

Seeking Alpha

Flag link: